The buying action over the last few months coupled with the past history of the stock definitely signal a buy. Very little selling in this range combined with past spikes in buying that led to the stock reaching the .20s and .40s in recent years is what makes this an attractive buy at this price.
Add that with the reported success of the previous melanoma trial, the complete response of one of the patients of the previous Phase I ovarian cancer trial, the FDA's approval of dendreon's provenge using a very similar treatment, and NWBO's seeming success with it's brain cancer treatment.
It all adds up to a buy.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM